Jurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00. Following the completion of the sale, the chairman directly owned 3,444,322 shares of the company’s stock, valued at approximately $26,211,290.42. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total value of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded down $0.04 during midday trading on Monday, hitting $7.67. 408,022 shares of the company’s stock were exchanged, compared to its average volume of 221,806. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The stock has a market cap of $643.44 million, a price-to-earnings ratio of -6.67 and a beta of 0.96. SOPHiA GENETICS SA has a 12-month low of $2.96 and a 12-month high of $7.88. The firm’s 50 day simple moving average is $5.63 and its 200 day simple moving average is $5.15.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC increased its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Archon Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after acquiring an additional 14,342 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter worth approximately $2,157,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on SOPH shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.